BRIEF-India's Biocon says USFDA accepts BLA for Mylan & co's proposed biosimilar Pegfilgrastim

Last Updated: Thu, Feb 16, 2017 18:40 hrs

Feb 16 (Reuters) - Biocon Ltd:

* Says U.S. FDA accepts Biologics License Application (BLA) for Mylan and Biocon's proposed biosimilar Pegfilgrastim for review

* Proposed biosimilar to Neulasta is used to reduce duration of neutropenia and incidence of fever associated with neutropenia in adults

* Says FDA goal date set under Biosimilar User Fee Act is Oct 9, 2017 Source text: Further company coverage:

More from Sify: